Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (NASDAQ: ALGS) has secured a $105 million private placement financing, led by a life sciences dedicated investment firm with participation from new and existing institutional investors. The company is selling 2,103,307 shares of common stock (1,427,000 voting and 676,307 non-voting), pre-funded warrants for up to 1,922,511 voting shares, and warrants for up to 2,012,909 voting shares.

The combined price is $26.0825 per share of common stock and accompanying warrant, with pre-funded warrants priced at $26.0824. The warrants will have an exercise price of $26.02 per share and will expire on February 13, 2032. The proceeds will fund the ALG-000184 Phase 2 clinical study in chronic hepatitis B virus infection and extend the company's cash runway into the second half of 2026.

Aligos Therapeutics (ALGS) has announced an inducement grant of non-qualified stock options to a newly hired employee. The grant, issued on December 10, 2024, allows for the purchase of 5,500 shares of company stock. The exercise price equals the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments, contingent on continued employment. The grant was made under Aligos' 2024 Inducement Plan, exclusively used for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced its participation in two major investor conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference at 11:00am ET and the Evercore ISI 7th Annual HealthCONx Conference at 4:15pm ET, both on December 3, 2024.

Management will conduct fireside chats at both events and participate in one-on-one meetings. The presentations will be webcast live on the company's investor relations website, with replays available for at least 30 days afterward.

Aligos Therapeutics (ALGS) presented positive data at The Liver Meeting 2024, highlighting two key developments: First, ALG-000184 showed sustained antiviral activity in chronic hepatitis B patients, with 100% of HBeAg-positive subjects achieving HBV DNA suppression at 84 weeks, and 91% of HBeAg-negative subjects reaching below detection limits at 48 weeks. Second, their THR-β agonist ALG-055009 demonstrated significant liver fat reduction in MASH patients, with up to 46.2% placebo-adjusted median reductions at 12 weeks. Notably, 70% of subjects achieved ≥30% liver fat reduction, and the drug showed effectiveness in patients on GLP-1 agonists. Both compounds were well-tolerated with no significant safety concerns.

Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company, reported its Q3 2024 financial results and recent business progress. The company highlighted positive topline HERALD data for ALG-055009 in MASH subjects, showing placebo-adjusted median relative reductions in liver fat of up to 46.2%. Aligos is completing Phase 2b enabling studies and exploring funding options, including partnerships. For ALG-000184, a potential best-in-class small molecule CAM-E for CHB, the company received positive regulatory feedback and announced a collaboration with Xiamen Amoytop Biotech. Additionally, ALG-097558 is progressing towards externally funded clinical studies for COVID-19.

Financially, Aligos reported cash, cash equivalents, and investments of $74.9 million as of September 30, 2024, down from $135.7 million at the end of 2023. The net loss for Q3 2024 was $19.3 million, compared to $18.0 million in Q3 2023. R&D expenses increased to $16.8 million, while G&A expenses decreased to $4.6 million.

Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to developing therapies for liver and viral diseases, announced it will release its third quarter 2024 financial results on November 6, 2024, after the U.S. markets close. The announcement will provide insights into the company's financial performance during this period.

Aligos Therapeutics (Nasdaq: ALGS) announced FDA clearance of its IND application for ALG-000184, a capsid assembly modulator for treating Chronic Hepatitis B (CHB). This allows the company to proceed with a Phase 1 Drug-Drug Interaction study and advance to Phase 2 clinical trials. The Phase 2 filing is expected in Q1 2025.

ALG-000184 is the first novel, oral drug candidate that can inhibit multiple components of the HBV lifecycle, potentially leading to more complete virus suppression. Data from ≤72 weeks of daily 300 mg doses showed best-in-class reductions in viral markers. The upcoming Phase 2 study will compare ALG-000184 to standard care in HBeAg-positive and negative CHB subjects.

The company anticipates enrolling patients next year and expects interim data readouts at upcoming scientific conferences. ALG-000184 has a clear regulatory path for chronic suppressive therapy with potential superiority over standard care.

Aligos Therapeutics (Nasdaq: ALGS) announced the acceptance of four abstracts for presentation at The Liver Meeting (TLM) 2024, hosted by the American Association for the Study of Liver Disease (AASLD) from November 15-19, 2024 in San Diego. The presentations include:

1. A late-breaker oral presentation on ALG-055009, a potential best-in-class THR-β agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), showcasing Phase 2a HERALD study results.

2. Three poster presentations: two on ALG-000184, a potential first-/best-in-class CAM-E for chronic hepatitis B (CHB), and one on the nonclinical toxicology profile of ALG-055009.

The abstracts highlight promising results for both drug candidates, including high viral suppression rates for ALG-000184 in CHB patients and significant liver fat reductions for ALG-055009 in MASH patients.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company focusing on liver and viral diseases, has announced the granting of non-qualified stock options to newly hired employees. The Compensation Committee of the Company's Board of Directors approved these Inducement Grants on October 8, 2024, totaling 95,000 shares of the Company's stock.

Notably, Dr. Hardean Achneck, the new Chief Medical Officer, received an option to purchase 75,000 shares. These grants, made under Aligos' 2024 Employment Inducement Award Plan, comply with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for new employees. The options have an exercise price equal to the closing price of Aligos' common stock on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.